X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
USFDA approved generic version of Gabapentin tablet, which is an anticonvulsant medication primarily used to treat partial seizures and neuropathic pain.
Lead Product(s): Gabapentin
Therapeutic Area: Neurology Product Name: Neurontin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Gabapentin inhibits the action of alpha-2-delta-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters. It is indicated for the management of postherpetic neuralgia.
Lead Product(s): Gabapentin
Therapeutic Area: Neurology Product Name: Neurontin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Gabapentin inhibits the action of alpha-2-delta-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters. It is indicated for the management of postherpetic neuralgia.
Lead Product(s): Gabapentin
Therapeutic Area: Neurology Product Name: Gabapentin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
With the acquisition, Endo controls all remaining development, approval, launch and commercialization activities for the product candidates, NVK009 (Gabapentin). Endo's Par Sterile Products business will commercialize the products in the United States.
Lead Product(s): Gabapentin,Pregabalin,Paracetamol
Therapeutic Area: Neurology Product Name: NVK009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endo International
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 02, 2022
Details:
The Merger will create a leading commercial pharmaceutical company with neurology, inflammation and pain products.
Lead Product(s): Gabapentin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Assertio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
